DISEASE & TREATMENT SETTING

ZUSDURI: recurrent Bladder Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Broader topic: Bladder Cancer

Source population: Not part of this definition
Disease extent: recurrent
Treatment line: Not part of this definition
Stage: Not part of this definition
Resectability: Not part of this definition

Biomarkers, prior therapy and derivation

molecular
prior therapy
derivation status: source-attested
derivation note: Scoped from the FDA approved indication for ZUSDURI (product label). Only dimensions stated in that wording are part of this definition.
source wording: 1 INDICATIONS AND USAGE ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Study evidence for this setting

Find a linked studyHow it was found

12 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT00022633 · Registry condition search · Scope: unclear

S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract

6 outcome links · 1 safety-group records · 3 quality-of-life measures

→

NCT00112905 · Registry condition search · Scope: unclear

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

4 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00407485 · Registry condition search · Scope: unclear

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

2 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00471536 · Registry condition search · Scope: unclear

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

6 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00478361 · Registry condition search · Scope: unclear

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

3 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00661609 · Registry condition search · Scope: unclear

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

5 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT00749892 · Registry condition search · Scope: unclear

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

2 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT02122172 · Registry condition search · Scope: unclear

Afatinib in Advanced Refractory Urothelial Cancer

6 outcome links · 2 safety-group records · 0 quality-of-life measures

→

NCT03154190 · Registry condition search · Scope: unclear

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

6 outcome links · 2 safety-group records · 0 quality-of-life measures

→

NCT03513952 · Registry condition search · Scope: unclear

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

6 outcome links · 3 safety-group records · 0 quality-of-life measures

→

NCT04267575 · Registry condition search · Scope: unclear

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

1 outcome links · 1 safety-group records · 0 quality-of-life measures

→

NCT04985604 · Registry condition search · Scope: unclear

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

6 outcome links · 2 safety-group records · 0 quality-of-life measures

→

Source relationships and population-mapping limitations

bindings
mappings

Download this complete draft source relationship record →

Preserved source evidence · Not medical advice